Medifast (NYSE:MED) released its earnings results on Thursday. The specialty retailer reported $1.32 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.33 by ($0.01), Briefing.com reports. The firm had revenue of $190.10 million during the quarter, compared to analysts’ expectations of $194.70 million. Medifast had a return on equity of 61.06% and a net margin of 11.22%. The firm’s revenue was up 36.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.14 earnings per share. Medifast updated its Q4 guidance to $1.03-.13 EPS.

Shares of MED traded down $27.64 during mid-day trading on Friday, reaching $74.36. The company had a trading volume of 3,379,003 shares, compared to its average volume of 294,247. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of 16.10 and a beta of 0.71. The firm has a fifty day simple moving average of $103.69 and a 200-day simple moving average of $117.92. Medifast has a fifty-two week low of $66.50 and a fifty-two week high of $165.70.

The business also recently declared a — dividend, which was paid on Thursday, November 7th. Shareholders of record on Friday, September 27th were issued a $0.75 dividend. The ex-dividend date was Thursday, September 26th. This represents a dividend yield of 2.8%. Medifast’s dividend payout ratio (DPR) is presently 64.94%.

Several analysts have commented on the stock. ValuEngine cut shares of Medifast from a “hold” rating to a “sell” rating in a research note on Friday. Zacks Investment Research cut shares of Medifast from a “buy” rating to a “hold” rating in a research note on Thursday, October 3rd. DA Davidson cut shares of Medifast from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $250.00 to $74.00 in a research note on Friday. Dougherty & Co cut shares of Medifast from a “buy” rating to a “neutral” rating in a research note on Friday. Finally, Jefferies Financial Group initiated coverage on shares of Medifast in a report on Thursday, July 25th. They issued a “buy” rating and a $130.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $134.00.

About Medifast

Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.

Featured Story: The Discount Rate – What You Need to Know

Earnings History for Medifast (NYSE:MED)

Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.